Insider Selling: Phreesia, Inc. (NYSE:PHR) CFO Sells 864 Shares of Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) CFO Balaji Gandhi sold 864 shares of the stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total value of $18,169.92. Following the completion of the transaction, the chief financial officer now directly owns 97,714 shares of the company's stock, valued at $2,054,925.42. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, September 10th, Balaji Gandhi sold 3,502 shares of Phreesia stock. The stock was sold at an average price of $23.25, for a total value of $81,421.50.

Phreesia Stock Performance

PHR traded down $0.45 during midday trading on Thursday, reaching $20.40. The company had a trading volume of 434,344 shares, compared to its average volume of 450,865. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The stock has a market cap of $1.17 billion, a PE ratio of -9.45 and a beta of 0.93. Phreesia, Inc. has a 12-month low of $12.05 and a 12-month high of $29.16. The business has a 50-day moving average price of $23.40 and a two-hundred day moving average price of $22.45.

Phreesia (NYSE:PHR - Get Free Report) last posted its earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.06. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The business had revenue of $102.12 million for the quarter, compared to analysts' expectations of $101.76 million. On average, sell-side analysts expect that Phreesia, Inc. will post -1.23 earnings per share for the current fiscal year.

Institutional Trading of Phreesia

A number of hedge funds have recently bought and sold shares of PHR. nVerses Capital LLC lifted its holdings in shares of Phreesia by 76.5% in the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company's stock worth $64,000 after acquiring an additional 1,300 shares during the last quarter. EntryPoint Capital LLC purchased a new position in Phreesia in the 1st quarter worth $169,000. Quadrature Capital Ltd bought a new stake in Phreesia in the first quarter worth $202,000. Lombard Odier Asset Management USA Corp bought a new stake in shares of Phreesia in the 2nd quarter valued at about $202,000. Finally, ProShare Advisors LLC boosted its holdings in Phreesia by 8.6% during the 1st quarter. ProShare Advisors LLC now owns 9,522 shares of the company's stock valued at $228,000 after acquiring an additional 751 shares during the period. Institutional investors own 92.10% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $34.00 target price on shares of Phreesia in a research note on Thursday, September 5th. KeyCorp reduced their price target on Phreesia from $27.00 to $25.00 and set an "overweight" rating for the company in a research report on Thursday, July 11th. JMP Securities restated a "market outperform" rating and set a $30.00 price target on shares of Phreesia in a research note on Thursday, September 5th. JPMorgan Chase & Co. boosted their target price on Phreesia from $27.00 to $28.00 and gave the stock an "overweight" rating in a report on Monday, September 9th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $29.00 price target on shares of Phreesia in a research note on Thursday, September 5th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $29.42.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.